|
Collaborative, Licensing and Other Arrangements (Details)
|
12 Months Ended | 36 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 3 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
USD ($)
Milestone
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2013
Milestone
|
Dec. 31, 2013
License Arrangement [Member]
License
|
Dec. 31, 2013
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
|
Dec. 31, 2012
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
|
Dec. 31, 2011
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
|
Oct. 31, 2011
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
|
Dec. 31, 2013
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
|
Dec. 31, 2012
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
|
Dec. 31, 2011
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
|
Dec. 31, 2010
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
|
Dec. 31, 2009
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
|
Sep. 30, 2008
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
|
Dec. 31, 2012
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 3 [Member]
USD ($)
|
Jul. 31, 2006
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 3 [Member]
USD ($)
|
Dec. 31, 2007
Pfizer Inc. [Member]
License Arrangement [Member]
USD ($)
|
Jan. 31, 2011
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
|
Jan. 31, 2011
Collaborative Arrangement [Member]
Servier [Member]
EUR (€)
|
Dec. 31, 2013
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
|
Dec. 31, 2012
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
|
Dec. 31, 2011
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
|
Dec. 31, 2013
Collaborative Arrangement [Member]
Servier [Member]
Sales And Development Milestones [Member]
USD ($)
|
Dec. 31, 2010
Collaborative Arrangement [Member]
Servier [Member]
Up-front Payment Arrangement [Member]
USD ($)
|
Sep. 30, 2010
Collaborative Arrangement [Member]
Servier - U.S. Perindopril Franchise [Member]
USD ($)
|
Dec. 31, 2013
Collaborative Arrangement [Member]
Servier - U.S. Perindopril Franchise [Member]
Product
|
Feb. 28, 2009
Collaborative Arrangement [Member]
Takeda [Member]
|
Nov. 30, 2006
Collaborative Arrangement [Member]
Takeda [Member]
|
Dec. 31, 2013
Collaborative Arrangement [Member]
Takeda [Member]
USD ($)
|
Dec. 31, 2012
Collaborative Arrangement [Member]
Takeda [Member]
USD ($)
|
Dec. 31, 2011
Collaborative Arrangement [Member]
Takeda [Member]
USD ($)
|
Dec. 31, 2013
Collaborative Arrangement [Member]
Takeda [Member]
Development Milestone [Member]
USD ($)
|
Feb. 28, 2009
Collaborative Arrangement [Member]
Takeda [Member]
Sales Milestone [Member]
USD ($)
|
Nov. 30, 2006
Collaborative Arrangement [Member]
Takeda [Member]
Sales Milestone [Member]
USD ($)
|
Nov. 30, 2008
Collaborative Arrangement [Member]
Novartis [Member]
USD ($)
|
Dec. 31, 2013
Collaborative Arrangement [Member]
Novartis [Member]
USD ($)
|
Nov. 30, 2008
Collaborative Arrangement [Member]
Novartis [Member]
Development Milestone [Member]
USD ($)
Product
|
Dec. 31, 2013
Collaborative Arrangement [Member]
Pfizer Inc. [Member]
Sales Milestone [Member]
USD ($)
|
Jan. 31, 2014
Non-arrangement Transactions [Member]
Pfizer Inc. [Member]
Development Milestone [Member]
USD ($)
|
Dec. 31, 2011
Non-arrangement Transactions [Member]
Pfizer Inc. [Member]
Development Milestone [Member]
USD ($)
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||||||||||||||||||||||||||||||||
| Deferred revenue, current | $ 15,000,000 | ||||||||||||||||||||||||||||||||||||||||
| Non-refundable upfront payment received | 15,000,000 | ||||||||||||||||||||||||||||||||||||||||
| Period for recognizing deferred revenue | 8 months | ||||||||||||||||||||||||||||||||||||||||
| Proceeds from loan | 19,500,000 | 15,000,000 | |||||||||||||||||||||||||||||||||||||||
| Total contract amount awarded | 28,000,000 | 3,000,000 | 64,800,000 | 16,300,000 | |||||||||||||||||||||||||||||||||||||
| Contractual term | 5 years | 3 years | |||||||||||||||||||||||||||||||||||||||
| Increase in deferred revenue | 900,000 | 1,100,000 | 2,000,000 | ||||||||||||||||||||||||||||||||||||||
| Recognition of deferred revenue | 4,700,000 | 2,500,000 | 100,000 | 4,400,000 | 6,600,000 | 18,600,000 | 21,200,000 | 2,000,000 | 100,000 | 1,200,000 | 2,000,000 | ||||||||||||||||||||||||||||||
| Future initial research and development expenses to be funded by counterparty | 50,000,000 | ||||||||||||||||||||||||||||||||||||||||
| Future other expenses to be funded by counterparty (in hundredths) | 50.00% | ||||||||||||||||||||||||||||||||||||||||
| Licensing and collaboration agreement revenue | 11,028,000 | 5,727,000 | 17,991,000 | 13,600,000 | 14,500,000 | 34,200,000 | |||||||||||||||||||||||||||||||||||
| Future milestone payments, maximum | 488,000,000 | 3,250,000 | 19,000,000 | 14,000,000 | |||||||||||||||||||||||||||||||||||||
| Future milestone payments, repurchase option not exercised, maximum | 827,000,000 | ||||||||||||||||||||||||||||||||||||||||
| Number of fixed-dose combination product candidates included in a portfolio of antihypertensive products from Servier | 3 | ||||||||||||||||||||||||||||||||||||||||
| License fees paid | 1,500,000 | ||||||||||||||||||||||||||||||||||||||||
| Future milestone payments with each additional future qualifying product candidate development, maximum | 20,750,000 | 1,700,000 | |||||||||||||||||||||||||||||||||||||||
| Royalty right expiration period | 10 years | 13 years 6 months | 20 years | ||||||||||||||||||||||||||||||||||||||
| Proceeds from collaborators | 6,200,000 | ||||||||||||||||||||||||||||||||||||||||
| Reduction in debt under restructured agreement | 7,500,000 | ||||||||||||||||||||||||||||||||||||||||
| Number of ongoing product programs with potential royalty right milestone payments | 2 | ||||||||||||||||||||||||||||||||||||||||
| Maximum borrowing capacity under agreement | 50,000,000 | ||||||||||||||||||||||||||||||||||||||||
| Research and development expenses funded through loan facility, maximum (in hundredths) | 75.00% | ||||||||||||||||||||||||||||||||||||||||
| Additional future milestone payments | 15,200,000 | ||||||||||||||||||||||||||||||||||||||||
| Number of licenses granted, minimum | 60 | ||||||||||||||||||||||||||||||||||||||||
| Proceeds from license fees received | 30,000,000 | ||||||||||||||||||||||||||||||||||||||||
| Number of undisclosed product candidates with milestone payments received | 12 | 10 | |||||||||||||||||||||||||||||||||||||||
| Percentage of milestone received | 25.00% | ||||||||||||||||||||||||||||||||||||||||
| Milestone received under the collaboration agreement | 7,000,000 | ||||||||||||||||||||||||||||||||||||||||
| Repayment of debt | $ 1,750,000 | ||||||||||||||||||||||||||||||||||||||||
| Euro to US Dollar exchange rates | 1.3766 | 1.3766 | 1.3766 | ||||||||||||||||||||||||||||||||||||||